Indapta Therapeutics

Executive Summary

Indapta Therapeutics is a private biotechnology company pioneering off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapies for cancer and autoimmune diseases. Based in San Diego, the company's platform leverages a novel genetic modification (FcRγ knockout) to enhance NK cell persistence, tumor targeting, and antibody-dependent cellular cytotoxicity (ADCC). Indapta's approach aims to overcome key limitations of NK cell therapies, such as limited in vivo expansion and susceptibility to inhibitory signals, while enabling scalable, off-the-shelf manufacturing. The company is currently in Phase 1 clinical development, evaluating its lead candidate for hematologic malignancies. With a strong focus on both oncology and autoimmune indications, Indapta represents a promising player in the allogeneic cell therapy space, though it remains early-stage with no approved products or disclosed partnerships. The next 12–18 months will be critical as the company reports initial clinical data and seeks to differentiate its platform in a competitive landscape.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 interim data readout for lead G-NK cell therapy in hematologic malignancies35% success
• Q4 2026IND filing for autoimmune indication (e.g., lupus or multiple sclerosis)25% success
• H2 2026Strategic partnership or licensing deal for manufacturing or co-development20% success